Subscribe to Niftyviews.com by email Add Team StockResearchers Headlines to your reader Share TSR with your friends SocialTwist Tell-a-Friend

24*7 CHAT ROOM

24*7 CHAT ROOM : TO LOGIN ENTER A USERNAME AND CLICK ON PROFILE.

ACTIVE CALLS- CALLS GIVEN BY TSR MODS IN CHAT ROOM

TO ENTER THE LIVE MARKET CHAT ENTER A USERNAME AND CLICK ON PROFILE.WISH TO JOIN OUR SERVICES.SIMPLY CLICK HERE FOR THE PROCEDURE.

GOOGLE SEARCH

ADS BY GOOGLE

Sunday, February 12, 2012

[T.S.R:18347] Jubilant Life-Update

Jubilant and Endo Pharmaceuticals Announce Successful Delivery of Early Milestones in Collaborative Discovery Program

Jubilant Biosys Ltd., a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd., announced today that they have achieved an early stage milestone in one of their collaborative programs with Chadds Ford, Pa., USA-based Endo Pharmaceuticals that has nominated a candidate into full development. The novel molecule, targeting cancer, is anticipated to go into clinical trials by late 2012. Jubilant and Endo will continue the collaboration in the development phase as well.

The multi-target collaboration that began three years ago focuses on Best in Class differentiated therapies to address the unmet needs of cancer patients worldwide.  The collaboration has since delivered multiple milestones across the discovery phase.Endo will pursue development and commercialization of the compound, while Jubilant becomes eligible to receive development milestones.

"We are very pleased and elated with this successful outcome, which is a result of the excellent collaboration between the scientists at Endo and Jubilant," said Sri Mosur, CEO & President, Global Drug Discovery and Development, Jubilant. "Jubilant has pioneered from India, a business model based on shared risk that enables it to demonstrate the differentiated and novel outcomes that Jubilant scientists are able to deliver through accelerated and affordable innovation to its many collaborators."

Sandeep GuptaEndo Pharmaceuticals, Senior Vice PresidentDiscovery & Early Development said, "I congratulate the Jubilant and Endo teams on achieving this important milestone. It was their outstanding collaborative work and ingenuity that enabled nomination of a development candidate ahead of schedule in less than two years since inception of this program. Initiation of this development program further validates Endo's unique collabrative drug discovery approach which aims to address unmet medical needs and improve patient outcomes".

About Us
Jubilant Biosys Ltd. is a Bengaluru based subsidiary of Jubilant Life Sciences Ltd, headquartered in Noida, India. Jubilant Biosys, provides integrated drug discovery and development solutions to the global pharmaceutical industry. It is a pioneer in collaborative discovery research and development and is engaged in multiple partnerships with global pharmaceutical industry in therapeutic areas of Oncology, CNS and CVMED. 
www.jubilantbiosys.com


--
For Anything related with Stock market be Online at
http://www.niftyviews.com/
 
Get free updates on your mobile phone. Sms "Join TSR " and send to 09223492234
 
FOR TRIAL STOCK/NIFTY/OPTION CALLS
 
 
You received this message because you are subscribed to Google Group "STOCKRESEARCHER" group.
To post to this group, send an email to STOCKRESEARCHER@googlegroups.com
 
To unsubscribe email
Stockresearcher-unsubscribe@googlegroups.com
 
for more info visit
http://groups.google.com/group/STOCKRESEARCHER?hl=en-GB
.
This is Not a Spam Mail.
Disclaimer :-
"The opinions expressed by the members on this board are based on
their individual experience and perceptions and to share information
with other members with the best of intentions to help fellow members
in investment decisions as equity investment is a risky venture."

0 comments:

Google
 

Sign by Dealighted - Coupons and Deals